mirage

Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Emanuele, Enzo
dc.contributor.author Bertona, Marco
dc.contributor.author Pareja Galeano, Helios
dc.contributor.author Fiuza Luces, María del Carmen
dc.contributor.author Morales Rojas, Javier Salvador
dc.contributor.author Sanchís-Gomar, Fabián
dc.contributor.author Lucía Mulas, Alejandro
dc.date.accessioned 2016-09-26T07:44:38Z
dc.date.available 2016-09-26T07:44:38Z
dc.date.issued 2016
dc.identifier.citation Emanuele, E., Bertona, M., Pareja-Galeano, H., Fiuza-Luces, C., Morales, J. S., Sanchis-Gomar, F., & Lucia, A. (2016). Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study. Neuro endocrinology letters, 37(3), 101-104. spa
dc.identifier.issn 0172780X
dc.identifier.issn 23544716
dc.identifier.uri http://hdl.handle.net/11268/5811
dc.description.abstract Muscle wasting in patients with cancer has been linked to an increased activity of nuclear factor κB (NF-κB) and higher circulating levels of activin-A (ActA), a negative growth factor for muscle mass. Baicalin is a natural flavonoid that can reduce skeletal muscle atrophy in animal models of cancer cachexia by inhibiting NF-κB. This pilot open-label study assessed the effects of baicalin supplementation (50 mg daily for 3 months) in cancer patients who showed involuntary weight loss >5% over the past 6 months. A total of 20 patients were investigated. Participants were evaluated at baseline and at the end of the 3-month study period for the following endpoints: 1) changes from baseline in serum NF-κB and ActA levels; and 2) change from baseline in lean body mass (LBM). We observed significant reduction in both NF-κB (p<0.05) and ActA (p<0.05) serum levels from baseline to 3 months. At 3 months, patients also showed a significant mean increase in LBM (+0.8 kg, p<0.05 compared with baseline). Our pilot open-label data suggest that baicalin supplementation is potentially useful for contrasting lean body mass reduction in cancer patients with involuntary weight loss, an effect which is likely mediated by the inhibition of negative growth factors for muscle mass. spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso eng spa
dc.title Baicalin supplementation reduces serum biomarkers of skeletal muscle wasting and may protect against lean body mass reduction in cancer patients: Results from a pilot open-label study spa
dc.type article spa
dc.description.impact 0.918 JCR (2016) Q4, 128/138 Endocrinology and Metabolism, 237/259 Neurosciences spa
dc.rights.accessRights openAccess spa
dc.subject.uem Enfermos de cáncer spa
dc.subject.uem Oncología spa
dc.subject.unesco Cáncer spa
dc.subject.unesco Salud spa
dc.description.filiation UEM spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record